BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO)

Historical Holders from Q2 2019 to Q3 2025

Symbol
BBIO on Nasdaq
Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
194M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
185M
Holdings value
$9.61B
% of all portfolios
0.023%
Grand Portfolio weight change
0%
Number of holders
387
Number of buys
217
Number of sells
-172
Average Value change %
0%
Average buys %
+0.002%
Average sells %
-0.004%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VANGUARD GROUP INC 8.68% $712M 16.5M The Vanguard Group 30 Jun 2025
VIKING GLOBAL INVESTORS LP 8.2% -15% $826M -$141M 15.9M -14.6% VIKING GLOBAL INVESTORS LP 14 Nov 2025
KKR Genetic Disorder L.P. 7% -31% $477M -$216M 13.3M -31.2% KKR Genetic Disorder L.P. 12 May 2025
Kumar Neil 5.41% $376M 10.5M NEIL KUMAR 31 Dec 2024

Institutional Holders of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 185M $9.61B -$158M $51.94 387
2025 Q2 189M $8.15B +$172M $43.18 357
2025 Q1 185M $6.41B +$325M $34.57 302
2024 Q4 177M $4.85B +$87.7M $27.44 260
2024 Q3 173M $4.39B -$68.1M $25.46 251
2024 Q2 175M $4.43B +$57.3M $25.33 249
2024 Q1 172M $5.3B +$162M $30.92 240
2023 Q4 166M $6.69B +$143M $40.37 246
2023 Q3 161M $4.24B +$304M $26.37 219
2023 Q2 150M $2.58B -$39.9M $17.20 196
2023 Q1 152M $2.53B +$155M $16.58 210
2022 Q4 145M $1.1B -$14.6M $7.62 175
2022 Q3 145M $1.44B +$48.7M $9.94 170
2022 Q2 140M $1.28B -$23.5M $9.08 153
2022 Q1 143M $1.45B -$24M $10.15 167
2021 Q4 142M $2.37B -$117M $16.68 181
2021 Q3 140M $6.56B -$165M $46.87 206
2021 Q2 143M $8.7B +$97.6M $60.96 197
2021 Q1 141M $8.69B +$1.24B $61.60 194
2020 Q4 121M $8.61B +$173M $71.11 160
2020 Q3 118M $4.39B +$21.6M $37.52 128
2020 Q2 117M $3.82B +$146M $32.61 114
2020 Q1 113M $3.27B +$162M $29.00 93
2019 Q4 101M $3.52B +$149M $35.05 85
2019 Q3 103M $2.22B +$112M $21.47 75
2019 Q2 99.9M $2.7B +$2.7B $26.97 60